公开(公告)号：US09517229B2

公开(公告)日：2016-12-13

申请号：US14236036

申请日：2012-07-27

Applicant: Andrew A. Protter ,  Jennifer Richer ,  Dawn Cochrane

Inventor： Andrew A. Protter ,  Jennifer Richer ,  Dawn Cochrane

IPC: A61K31/4184 ,  A61K31/4166

CPC classification number: A61K31/4184 ,  A61K31/4166

Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.

Abstract translation: 本公开描述了一种或多种落入结构式I，II，III，IV，V或VI中的一种或多种的范围内用于治疗三阴性乳腺癌的化合物的用途，所述化合物用于治疗乳腺癌包括那些式 I，II，III，IV，V或VI抑制乳腺癌细胞的增殖和/或导致乳腺癌细胞死亡，特别是三阴性乳腺癌。

公开(公告)号：US20140100256A1

公开(公告)日：2014-04-10

申请号：US14023637

申请日：2013-09-11

Applicant: BEND RESEARCH ,  ASTELLAS PHARMA INC. ,  MEDIVATION PROSTATE THERAPEUTICS, INC.

Inventor： Douglas Alan Lorenz ,  Sanjay Konagurthu ,  Randy J. Wald ,  Jason A. Everett ,  Sheila Matz ,  Yuuki Takaishi ,  Toshiro Sakai ,  Ryousuke Irie ,  Shinsuke Oba ,  Hiroyasu Toyota ,  Koji Nishimura ,  Atsushi Kanbayashi

IPC: A61K31/4166 ,  A61K9/10 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61K9/2054 ,  A61K9/10 ,  A61K9/16 ,  A61K9/1652 ,  A61K9/2095 ,  A61K31/4164 ,  A61K31/4166 ,  A61K47/32 ,  A61K47/38 ,  C07D233/86

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract translation: 本公开提供了恩扎洛胺的制剂及其用于治疗过度增殖性疾病的用途。

公开(公告)号：US09174943B2

公开(公告)日：2015-11-03

申请号：US13785504

申请日：2013-03-05

Applicant: Rajendra Parasmal Jain ,  Remy Angelaud ,  Andrew Thompson ,  Carol Lamberson ,  Scott Greenfield

Inventor： Rajendra Parasmal Jain ,  Remy Angelaud ,  Andrew Thompson ,  Carol Lamberson ,  Scott Greenfield

IPC: C07D233/86 ,  C07D235/02 ,  C07D233/40 ,  C07D233/42

CPC classification number: C07D233/86 ,  C07C231/12 ,  C07C237/30 ,  C07D235/02

Abstract: Processes are provided for the synthesis of diarylthiohydantoin and diarylhydantoin compounds. Medicinal products containing the same find particular use in treating prostate cancer, including castration-resistant prostate cancer and/or hormone-sensitive prostate cancer.

Abstract translation: 提供了二芳基硫代乙内酰脲和二芳基乙内酰脲化合物的合成方法。 含有该药物的药物在治疗前列腺癌方面特别有用，包​​括抗阉割前列腺癌和/或激素敏感性前列腺癌。

公开(公告)号：US20120184580A1

公开(公告)日：2012-07-19

申请号：US13263728

申请日：2010-04-09

Applicant: Sarvajit Chakravarty ,  Rajendra Parasmal Jain

Inventor： Sarvajit Chakravarty ,  Rajendra Parasmal Jain

IPC: A61K31/4166 ,  A61P35/00 ,  C07D401/10 ,  A61K31/454 ,  C07D233/86 ,  C07D403/10

CPC classification number: C07D233/76 ,  C07D233/86

Abstract: Substituted di-arylhydantoin and di-arylthiohydantoins are provided and may find use as androgen receptor modulators. The compounds may find particular use in treating prostate cancer, including CRPC and/or hormone-sensitive prostate cancer.

Abstract translation: 提供了取代的二芳基乙内酰脲和二芳基硫代乙内酰脲，可以用作雄激素受体调节剂。 这些化合物可以特别用于治疗前列腺癌，包括CRPC和/或激素敏感性前列腺癌。

公开(公告)号：US20140179749A1

公开(公告)日：2014-06-26

申请号：US14023878

申请日：2013-09-11

Applicant: Bend Research ,  ASTELLAS PHARMA INC. ,  MEDIVATION PROSTATE THERAPEUTICS, INC.

Inventor： Douglas Alan Lorenz ,  Sanjay Konagurthu ,  Randy J. Wald ,  Jason A. Everett ,  Sheila Matz ,  Yuuki Takaishi ,  Toshiro Sakai ,  Ryousuke Irie ,  Shinsuke Oba ,  Hiroyasu Toyota ,  Koji Nishimura ,  Atsushi Kanbayashi

IPC: A61K9/16 ,  A61K9/20 ,  A61K31/4164

CPC classification number: A61K9/2054 ,  A61K9/10 ,  A61K9/16 ,  A61K9/1652 ,  A61K9/2095 ,  A61K31/4164 ,  A61K31/4166 ,  A61K47/32 ,  A61K47/38 ,  C07D233/86

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

公开(公告)号：US20130331421A1

公开(公告)日：2013-12-12

申请号：US13925507

申请日：2013-06-24

Applicant: Rajendra Parasmal Jain ,  Jacqueline A. Gibbons

Inventor： Rajendra Parasmal Jain ,  Jacqueline A. Gibbons

IPC: C07D233/86 ,  C07D233/72

CPC classification number: C07D233/86 ,  A61K31/4166 ,  C07D233/72 ,  C07D233/74 ,  C07D233/84

Abstract: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.

Abstract translation: 提供了包含特定的二芳基乙内酰脲和二芳基硫代乙内酰脲化合物的组合物，例如药物组合物，或其盐或溶剂合物。 还描述了分离和纯化形式的化合物，单位剂型，基本上纯的化合物的组合物和包含该化合物的试剂盒也是如此。 其化合物及其药物组合物可用于预防和/或治疗各种病症，包括前列腺癌，帕金森病，阿尔茨海默病等。

公开(公告)号：US10111861B2

公开(公告)日：2018-10-30

申请号：US15373914

申请日：2016-12-09

Applicant: Medivation Prostate Therapeutics LLC ,  The Regents of the University of Colorado, a body corporate

Inventor： Andrew A. Protter ,  Jennifer Richer ,  Dawn Cochrane

IPC: A61K31/4184 ,  A61K31/4166

Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.

公开(公告)号：US09023879B2

公开(公告)日：2015-05-05

申请号：US13925507

申请日：2013-06-24

Applicant: Rajendra Parasmal Jain ,  Jacqueline A. Gibbons

Inventor： Rajendra Parasmal Jain ,  Jacqueline A. Gibbons

IPC: A61K31/4166 ,  C07D233/72 ,  C07D233/86 ,  C07D233/74 ,  C07D233/84

CPC classification number: C07D233/86 ,  A61K31/4166 ,  C07D233/72 ,  C07D233/74 ,  C07D233/84

Abstract: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.

Abstract translation: 提供了包含特定的二芳基乙内酰脲和二芳基硫代乙内酰脲化合物的组合物，例如药物组合物，或其盐或溶剂合物。 还描述了分离和纯化形式的化合物，单位剂型，基本上纯的化合物的组合物和包含该化合物的试剂盒也是如此。 其化合物及其药物组合物可用于预防和/或治疗各种病症，包括前列腺癌，帕金森病，阿尔茨海默病等。

公开(公告)号：US20140296312A1

公开(公告)日：2014-10-02

申请号：US14236036

申请日：2012-07-27

Applicant: Andrew A. Protter ,  Jennifer Richer ,  Dawn Cochrane

Inventor： Andrew A. Protter ,  Jennifer Richer ,  Dawn Cochrane

IPC: A61K31/4184 ,  A61K31/4166

CPC classification number: A61K31/4184 ,  A61K31/4166

Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.

Abstract translation: 本公开描述了一种或多种落入结构式I，II，III，IV，V或VI中的一种或多种的范围内用于治疗三阴性乳腺癌的化合物的用途，所述化合物用于治疗乳腺癌包括那些式 I，II，III，IV，V或VI抑制乳腺癌细胞的增殖和/或导致乳腺癌细胞死亡，特别是三阴性乳腺癌。

公开(公告)号：US08524755B2

公开(公告)日：2013-09-03

申请号：US13202970

申请日：2010-02-24

Applicant: Rajendra Parasmal Jain ,  Jacqueline A. Gibbons

Inventor： Rajendra Parasmal Jain ,  Jacqueline A. Gibbons

IPC: A61K31/4166 ,  C07D233/72

CPC classification number: C07D233/86 ,  A61K31/4166 ,  C07D233/72 ,  C07D233/74 ,  C07D233/84

Abstract: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.